Generic Biologics: Xigris Approval Suggests Precedent For FDA, GPhA Says
Executive Summary
FDA's analysis of manufacturing process changes for Xigris is the latest indication that some form of a generic biologics approval process is feasible, the Generic Pharmaceutical Association says
You may also be interested in...
Hepatitis B Vaccine Labels Show Generic Biologics Possible, GPhA Says
Labeling for GlaxoSmithKline's Engerix-B hepatitis B vaccine demonstrates the feasibility of "generic" biologics, Generic Pharmaceutical Association representative William Schultz told a June 23 Senate Judiciary Committee hearing on follow-on biologics
Hepatitis B Vaccine Labels Show Generic Biologics Possible, GPhA Says
Labeling for GlaxoSmithKline's Engerix-B hepatitis B vaccine demonstrates the feasibility of "generic" biologics, Generic Pharmaceutical Association representative William Schultz told a June 23 Senate Judiciary Committee hearing on follow-on biologics
Generic Biologics On FDA Fast Track?: “Follow-On” Process Under Debate
Data requirements for generic biologics approved under the 505(b)(2) process will be taken up by FDA over the next six months, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said